Thomas M. Roberts

This paper develops GT220, a selective PI3Kβ inhibitor, showing efficacy in PTEN-deficient cancers while sparing normal cells.

The paper demonstrates that statin-dye conjugates are selectively taken up by KRAS mutant cancer cells through enhanced macropinocytosis, enabling targeted killing of these cells without affecting KRAS wild-type cells.

This study shows CDK12 inhibition both downregulates and upregulates gene expression, with implications for cancer therapy.

This study shows that PTEN loss in cancer cells activates intrinsic interferon signaling, leading to immune resistance and vulnerability to CDK12 inhibition.